Mon, Nov 24, 2014, 4:59 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

ri66 378 posts  |  Last Activity: 2 hours 40 minutes ago Member since: Aug 15, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    technicals

    by jake_718 3 hours ago
    ri66 ri66 2 hours 40 minutes ago Flag

    There is not relevance technically to anything you wrote other then AF's damage. People like him and others around here can lie about Ampio all they want, when the news comes out the liars will stop and just go away, probably go away mad but who cares I'll be in Jamaica.

  • Reply to

    ri66s Austrailian Study

    by imprvngmyavg 4 hours ago
    ri66 ri66 2 hours 43 minutes ago Flag

    5/31/2011 3:55 PM ET

    Ampio Pharmaceuticals, Inc. (AMPE: Quote), Tuesday said Ampion, its biologic anti-inflammatory agent, received ethics board approval for a Phase 1B clinical trial in Australia. Ampio said the trial is designed to demonstrate efficacy in the treatment of osteoarthritis of the knee and to confirm patient safety and tolerance.

    The trial started before your date foo, it was announced then of the expansion of the trial. Almost five years ago, now the drug was in development five years before that fool. That adds up to almost ten years of testing and trials and now pivotal trials that will be quite a shock to the haters like you..... wierdo.....

  • Latest Update highlights: (my thoughts in quotes)
    Open label 7 patient Strut
    The 20-week data is expected in the fourth quarter of 2014. Includes MRI
    (we are deep in Q4 could be tomorrow)

    Manufacturing validation runs are on schedule. Multiple engineering runs were performed and commercial Ampion™ vials will be manufactured in the first quarter of 2015. (shots for you and me just after Christmas)

    OptimEyes study is complete and included 355 patients. The data is being locked by our CRO. Once data validation is completed, it will be transmitted to an independent statistician for analysis and afterward submitted to the FDA for review with our request for a meeting we anticipate meeting with the FDA following the holidays.
    (just over a month away)

    Stride 320 patients. This study is being conducted in 14 sites in the USA. The STRIDE study will conclude in the second quarter of 2015." (Results to follow)

    Strut study 40 patients
    Results at 20 weeks (end of FDA study) will be available in the first quarter of 2015.
    (Just over a month away)

    We have also learned that, prior to Ampion™, no therapy has produced sufficient clinical improvement to determine which parameters are the important ones to study. The MRI data to date is suggesting that certain areas in the joint are changing greater than others but it is important to look at each compartment separately.

    These MRI's are being reviewed and analyzed by experts in the field. Almost all studies examining the changes produced by osteoarthritis in the knee are 12 to 24 months in duration. However, it was considered worthwhile to begin the process early to see if changes at 12 weeks could indicate the most valuable parameters to follow. Because of the complexities in analyzing the physical signals as well as proper timing in relation to the various compartments evaluated, the complete results and conclusions were not made available to the company as yet.

    The news to come is going to knock the socks off the shorties

  • Reply to

    Bill Williams is still short.

    by ri66 Nov 21, 2014 1:11 PM

    We are up six cents right now this morning 11:28 EST, won't be long before Bill comes out with some funk about more goat studies or herbal remedies being our next competitors. When he or anyone is short a stock, can anything they say here on this board be taken as fact?

  • Reply to

    PH1/2 Precursors to SPRING Study

    by thetrustysteed 22 hours ago

    Why would Optina not remain an oral alternative to injections?

  • Reply to

    PH1/2 Precursors to SPRING Study

    by thetrustysteed 22 hours ago

    The Australian trial doctors and clinical reps and patients were amazed at our results, read up on their remarks. Also that was roughly five years ago.

  • Reply to

    billwilliams836...

    by superforce_57 Nov 21, 2014 1:35 PM

    I shall bump this with righteous indignation.

  • Now Mr. Bill has rolled out some herbal studies as our next competitive challenge, yea that'll grow cartilage for sure! WRONG data again Mr. Bill. Answer my challenge above. Gain respect ---or continue with your shorty ways.

  • Mr. Bill the LATEST PR stated this data to be read in Q4 we as you know are knee deep into this quarter and this news blast replete with MRI data could be as early as tomorrow morning, jeesh long winter wait indeed.... Your chess game today is tiresome, just go long the stock and stop with the funky posts please.

  • Reply to

    Traumeel & Zeel (Tr14/Ze14)

    by arikofunit101 23 hours ago

    Man you are busy today setting up for you baloney posts for next week. You think Ampion's competitors are herbs, and KL2 studies on drugs and goat studies etc.

    Bill, AMPE has no more downside in it, better get yourself straight on this stock or you'll be punished with the rest of the 12 million shorts foo.
    Get right with your god Mr. Bill, it's Sunday somewhere in the world.

  • Reply to

    Traumeel & Zeel (Tr14/Ze14)

    by arikofunit101 23 hours ago

    Forgot to mention in Bills hypothesis that our nearest term competitior was still doing goat studies. Are the shorts running out of valid information, are we just pushing pieces on a chess board with them until the news breaks, jeesh we need to quiet the cabal once and for all.

  • Reply to

    Traumeel & Zeel (Tr14/Ze14)

    by arikofunit101 23 hours ago

    Exactly. The noise in the background just got a little quieter.

  • Not a fan of the paranoid label, I'll call it guarded. I am in defense of a company with no bad news but frozen samples, lame. We are under attack, and yes here as would Bill you failed to answer my question: What is a 95% reduction in pain as we saw in the Super 7, what is that on the MCID scale other than DOMINANT.

    If you increased your postion you are not alone, I have as well and will steadfastly defend this company until given a reason not to. Believe me, frozen samples and the subsequent price decline with price manipulation and liars here and there around every corner and the hedgies quants darkstools, you name it we are under attack. I apologize right now to you and perhaps Bill if he is legitimately long, yes even Bill for interrupting an otherwise informative disucssion.

    But the question above remains unanswered.

  • ri66 ri66 Nov 23, 2014 3:10 PM Flag

    The super 7 showed a 95% reduction in pain, what is this in the MCID scale? Answer: Dominant!

    Please don't be short here as well as Bill, for all we know trusty, you could be Bill.

  • ri66 ri66 Nov 22, 2014 8:27 PM Flag

    When a known short says great job I raise my hand and ask questions. First question, what if it points to a more optimistic view of Ampion?
    Steed wrote:
    The exclusion of KL2 patients will benefit this. If we can trust that the open label results are reasionably accurate, then 100% (7 of 7) met MCID fof 40% relative reduction in pain. That's pretty damn good.

    So we see that Ampion multiple injection will outperform MI saline or your TR14/ZE combo.
    Pretty damn good huh Mr. Bill?

  • Reply to

    Bill Williams is still short.

    by ri66 Nov 21, 2014 1:11 PM
    ri66 ri66 Nov 21, 2014 7:58 PM Flag

    I guess you clocked in hater, you have nothing to contribute little man. fondness for facts: the first trial of Ampion was in Australia just about five years ago. The trial doctors were amazed at Ampion's effectivness. The drug was further developed five years prior to that fool. The symbol change has nothing to do with the development of the drug. Serum Albumin has been around as long as humans have. You are a complete idiot and any review of your posting history shows that it seems you can't wait to slam me while I have you on ignore and that is pitiful. Why is it you never ever talk about the company or it's drugs? Do you even know about our company or is it your mission to bring a loyal shareholder down each day. I only post facts so get a grip little man.
    Pitiful little man.

  • Reply to

    Bill Williams is still short.

    by ri66 Nov 21, 2014 1:11 PM
    ri66 ri66 Nov 21, 2014 4:08 PM Flag

    Up six cents today when Bill hurriedly came out of the shadows and rolled out some funk, quarter million shares traded today and essentially went nowhere, thanks guys you achieved your goal today, which was? To bring it down 2 cents?

  • ri66 ri66 Nov 21, 2014 2:14 PM Flag

    Find it odd that Mr. Bill---Ooooonoooo, can't really argue with what is postulated here above but does wax poetic scientifically about near term competitors doing goat studies being a threat to Ampion, ok where is their 95% level of pain reduction in 12 weeks? Where is their pivotal human trial? Where is their MRI data? Where is their potential threat? I hope to hear from all the short shills here on this thread.

  • Reply to

    Bill Williams is still short.

    by ri66 Nov 21, 2014 1:11 PM
    ri66 ri66 Nov 21, 2014 2:08 PM Flag

    NoMerrit, we are talking Bill's goat studies being comparable to 10 years of Ampion's history in human now pivotal trials. Where in your charts is that stuff?

  • Reply to

    Bill Williams is still short.

    by ri66 Nov 21, 2014 1:11 PM
    ri66 ri66 Nov 21, 2014 2:07 PM Flag

    Moronicanus, I did forget to include you on that short shill baloney list, sorry.

ARNA
4.14-0.03(-0.72%)4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.